Q-omics provides the consensus-scored METTL14-DT profile across patient tissues and cancer cell-line models. METTL14-DT expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, METTL14-DT is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, METTL14-DT RNA expression shows 17,813 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KICH, LIHC, and UVM as cancer lineages where METTL14-DT shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for METTL14-DT — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes METTL14-DT survival associations across molecular data types. METTL14-DT RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible METTL14-DT RNA expression–survival associations across cancer types. High METTL14-DT expression shows unfavorable associations in KICH, KIRC and GBM, but favorable associations in BRCA, BLCA and LGG. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KICH as the clearest survival context for METTL14-DT RNA expression.
This table summarizes METTL14-DT tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for METTL14-DT. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. METTL14-DT shows lower tumor expression in THCA and higher tumor expression in LIHC, CHOL, PAAD, LUSC and LUAD. The LIHC box plot shows higher METTL14-DT RNA expression in tumor versus normal tissue (log2 FC = +0.027, t-test p = .001).
This table shows molecular features associated with METTL14-DT in patient tissues and cancer cell lines. In patient samples, METTL14-DT shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
